GlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
"We believe GMI-1271 has the potential to address important unmet needs
for individuals with relapsed or refractory AML, as well as for older
AML patients, for whom the standard of care often fails to provide
outcomes as positive as those seen in other patient groups," said
The Fast Track Designation is designed to facilitate development and expedite review of experimental therapies that address the unmet medical needs of patients with serious conditions.
AML is a cancer of immature white blood cells that starts in the bone
marrow but can quickly spread into the blood, lymph nodes, liver,
spleen, central nervous system, and testicles. Each year in
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with AML cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. In preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH), GMI-1271 was also associated with a reduction of chemotherapy-induced neutropenia and chemotherapy-induced mucositis.
News Provided by Acquire Media